Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Company Overview

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors. In parallel, Tiziana’s wholly owned biologic portfolio includes foralumab, a fully human anti‐CD3 monoclonal antibody investigated for autoimmune and neuroinflammatory conditions, and TZLS‐501, an anti‐interleukin‐6 receptor antibody initially evaluated for acute respiratory distress syndrome associated with infectious diseases.

Tiziana Life Sciences serves markets in North America and Europe, collaborating with academic centers and contract research organizations to conduct its clinical programs. The company’s multidisciplinary team combines expertise in translational research, medicinal chemistry and antibody engineering to support its pipeline from early discovery through clinical development.

Since joining Tiziana as chief executive officer in 2019, Dr. Bahija Jallal has leveraged her experience in biotechnology and immunotherapy to steer the company’s strategic direction. Supported by a board of directors and scientific advisory board with extensive pharmaceutical development backgrounds, Tiziana is advancing its programs toward regulatory milestones with the goal of addressing unmet needs in cancer and immune‐mediated diseases.

Key Stats

• Today's Range: $1.78 to $1.87
• 50-Day Range: $1.47 to $2.50
• 52-Week Range: $0.63 to $2.60
• Volume: 64,810 shs
• Average Volume: 579,444 shs
• Market Capitalization: $211.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Tiziana Life Sciences Stock Analysis - MarketRank™

Tiziana Life Sciences scored higher than 5% of companies evaluated by MarketBeat, and ranked 915th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Tiziana Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Tiziana Life Sciences has a P/B Ratio of 45.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.04% of the float of Tiziana Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Tiziana Life Sciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tiziana Life Sciences has recently increased by 12.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tiziana Life Sciences does not currently pay a dividend.

Dividend Growth

Tiziana Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.04% of the float of Tiziana Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Tiziana Life Sciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tiziana Life Sciences has recently increased by 12.73%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Tiziana Life Sciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

MarketBeat Follows

4 people have added Tiziana Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

TLSA Stock Analysis - Frequently Asked Questions

How have TLSA shares performed this year?

Tiziana Life Sciences' stock was trading at $0.6962 at the start of the year. Since then, TLSA stock has increased by 160.0% and is now trading at $1.81.

When did Tiziana Life Sciences IPO?

Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Who are Tiziana Life Sciences' major shareholders?

Tiziana Life Sciences' top institutional investors include Zhang Financial LLC (0.08%), Jane Street Group LLC (0.02%), Marshall Wace LLP (0.02%) and Simplex Trading LLC.

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO) and Pfizer (PFE).

Company Calendar

• Today: 9/10/2025
• Next Earnings (Estimated): 10/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLSA
• CIK: 1723069
• Web: www.tizianalifesciences.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.02
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.04 per share
• Price / Book: 46.25

Miscellaneous

• Outstanding Shares: 116,848,000
• Free Float: 70,319,000
• Market Cap: $216.17 million
• Optionable: Optionable
• Beta: -0.36